On August 5, Cencora Inc. rose 3.78% in regular trading, trading at $318.08/share, with turnover of $242 million. The move was driven by the company's pre-market Q3 earnings release, which exceeded Wall Street expectations across the board, accompanied by an upward revision to full-year guidance.

Specifically, Q3 adjusted EPS came in at $4.48, surpassing the consensus estimate of $4.35 by approximately 3%, representing a 12% year-over-year increase from $4.00. Revenue totaled $84.754 billion, ahead of the $84.315 billion estimate. The company raised its fiscal 2026 adjusted EPS outlook to $17.75–$17.95, up from the prior range of $17.65–$17.90, compared with the FactSet consensus of $17.78.

On the strategic front, management emphasized during the earnings call that the company's capital allocation priorities are centered on retina and oncology, with future M&A strictly targeting accretive bolt-on acquisitions rather than broad-based expansion. The company previously announced an $1.1 billion acquisition of EyeSouth Partners' retina business and a CAR-T cell therapy distribution agreement with Kite, reinforcing its specialty focus.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)